Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc said on Wednesday its cancer therapy Keytruda failed to meet the main goal of a late-stage trial testing it in patients with head and neck cancer.

Merck's Keytruda fails head and neck cancer trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma

Seagen

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Is Merck Stock A Buy With A Possible Seagen Buyout Right Around The Corner?

AstraZeneca

Merck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction.  The action follows the recommendation of an.

Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study

Merck & Co.'s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant's earnings later this month, though the talks remain on track, according to people familiar with the matter.

Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say

Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.

Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate

American Express

Chevron

Travelers

Verizon

These 6 Dow stocks to buy on the dip might produce excellent returns for the long-term investor. They have low valuations, good earnings growth, and high dividend yields.

6 Dow Stocks to Buy on the Dip

Bayer AG

Jazz Pharmaceuticals

Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.

3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health

British American Tobacco

Enbridge

Toronto-Dominion Bank

Texas Instruments

V.F.

On an annualized inflation-adjusted basis, the stock market just had its worst first half since 1872. Yet sleeping well at night, even if you're retired, is still easily accomplished with the world's best high-yield blue-chips.

7 High-Yield Retirement Dream Blue-Chips For This Recession

Merck & Co. Inc. said Wednesday it will make a $290 million upfront payment to Orion Corp. as part of an agreement to develop and commercialize Orion's prostate cancer treatment ODM-208. Merck said the payment will be included in its third-quarter earnings report.

Merck to pay Orion $290 million upfront to develop, commercialize prostate cancer treatment

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Orion Announce Global Collaboration for Development of ODM-208, an Investigational Agent in Metastatic Castration-Resistant Prostate Cancer

Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The Dow struggled today, as investors prepared for a busy week full of new economic data and the beginning of earnings season.

Investors Bought This Pharma Stock Despite the Dow's 164-Point Drop Today

BioNTech SE

Moderna

Pfizer

Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.

PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents

Bank of America

Microsoft

Realty Income Corp

PepsiCo

Which of these dividend stocks do you have on your watchlist right now?

What Stocks To Buy Today? 5 Dividend Stocks To Watch In This Bear Market

Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%.

What's Happening With Merck Stock?

Cigna

Valero Energy

All three sport strong Zacks Ranks - a significant perk that instills confidence in these companies' share performances moving forward.

3 Large-Cap Stocks up More Than 20% Year-To-Date

Home Depot

JPMorgan Chase & Co

Coca-Cola

We have narrowed our search to four Dow stocks. These are: HD, KO, MRK and JPM.

Buy These 4 Blue-Chip Stocks to Strengthen Your Portfolio

Amgen

CRISPR Therapeutics

Exelixis

iShares Nasdaq Biotechnology ETF

Ionis Pharma

Twist Bioscience Corp

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared first on InvestorPlace.

7 Best Biotech Stocks to Buy in July 2022

A new Wall Street Journal report revealed that Merck is in “advanced talks” to acquire Seattle-area biotech giant Seagen in a deal that could be worth $40 billion or more.

Report: Merck in ‘advanced talks' to acquire Seattle-area biotech giant Seagen for around $40B

Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.

Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ

Shares of Seagen Inc (NASDAQ: SGEN) are up 3.0% this morning on a report that Merck & Co Inc (NYSE: MRK) is in advanced talks to buy the cancer drug specialist for at least $40 billion. Dr Gottlieb reacts to the news According to the Wall Street Journal, the pharma giant is willing to pay […] The post Merck nears Seagen takeover: ‘question is how does FTC look at this?

Merck nears Seagen takeover: ‘question is how does FTC look at this?'

Seagen (SGEN) stock is getting a boost on Thursday as rumors circulate that Merck (MRK) is considering a buyout of the biotechnology company. The post Seagen (SGEN) Stock Pops on Merck Buyout Rumors appeared first on InvestorPlace.

Seagen (SGEN) Stock Pops on Merck Buyout Rumors

The drugmaker is defying the stock market sell-off right now.

Merck's Oncology Business Will Help It Crush the Bear Market

Seagen Inc (NASDAQ: SGEN) shares are trading higher Thursday following reports suggesting Merck & Company Inc (NYSE: MRK) is in advanced talks to acquire the company. According to a Wall Street Journal report citing people familiar with the matter, the two companies are.

Why Merck Is Sending Seagen Stock Higher Today

Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Seagen Inc (NASDAQ: SGEN), and an agreement on a purchase is expected in the next few weeks, Wall Street Journal reported citing people familiar with the matter. The potential deal could be worth roughly $40.

News for Merck Stock (MRK)